Article ; Online: Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study.
The Journal of antimicrobial chemotherapy
2024 Volume 79, Issue 2, Page(s) 453–461
Abstract: Objectives: To assess the impact of piperacillin/tazobactam MICs on in-hospital 30 day mortality in patients with third-generation cephalosporin-resistant Escherichia coli bloodstream infection treated with piperacillin/tazobactam, compared with those ... ...
Abstract | Objectives: To assess the impact of piperacillin/tazobactam MICs on in-hospital 30 day mortality in patients with third-generation cephalosporin-resistant Escherichia coli bloodstream infection treated with piperacillin/tazobactam, compared with those treated with carbapenems. Methods: A multicentre retrospective cohort study was conducted in three large academic hospitals in Italy between 2018 and 2022. The study population comprised patients with monomicrobial third-generation cephalosporin-resistant E. coli bloodstream infection, who received either piperacillin/tazobactam or carbapenem therapy within 48 h of blood culture collection. The primary outcome was in-hospital 30 day all-cause mortality. A propensity score was used to estimate the likelihood of receiving empirical piperacillin/tazobactam treatment. Cox regression models were performed to ascertain risk factors independently associated with in-hospital 30 day mortality. Results: Of the 412 consecutive patients included in the study, 51% received empirical therapy with piperacillin/tazobactam, while 49% received carbapenem therapy. In the propensity-adjusted multiple Cox model, the Pitt bacteraemia score [HR 1.38 (95% CI, 0.85-2.16)] and piperacillin/tazobactam MICs of 8 mg/L [HR 2.35 (95% CI, 1.35-3.95)] and ≥16 mg/L [HR 3.69 (95% CI, 1.86-6.91)] were significantly associated with increased in-hospital 30 day mortality, while the empirical use of piperacillin/tazobactam was not found to predict in-hospital 30 day mortality [HR 1.38 (95% CI, 0.85-2.16)]. Conclusions: Piperacillin/tazobactam use might not be associated with increased mortality in treating third-generation cephalosporin-resistant E. coli bloodstream infections when the MIC is <8 mg/L. |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
MeSH term(s) | Humans ; Ceftriaxone ; Carbapenems/pharmacology ; Carbapenems/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Piperacillin/therapeutic use ; Escherichia coli ; Retrospective Studies ; Propensity Score ; Penicillanic Acid/therapeutic use ; Piperacillin, Tazobactam Drug Combination ; Escherichia coli Infections/drug therapy ; Cohort Studies ; Sepsis/drug therapy | ||||||||||
Chemical Substances | Ceftriaxone (75J73V1629) ; Carbapenems ; Anti-Bacterial Agents ; Piperacillin (X00B0D5O0E) ; Penicillanic Acid (87-53-6) ; Piperacillin, Tazobactam Drug Combination (157044-21-8) | ||||||||||
Language | English | ||||||||||
Publishing date | 2024-01-02 | ||||||||||
Publishing country | England | ||||||||||
Document type | Observational Study ; Journal Article | ||||||||||
ZDB-ID | 191709-2 | ||||||||||
ISSN | 1460-2091 ; 0305-7453 | ||||||||||
ISSN (online) | 1460-2091 | ||||||||||
ISSN | 0305-7453 | ||||||||||
DOI | 10.1093/jac/dkad404 | ||||||||||
Shelf mark |
|
||||||||||
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1197: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 124: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.